CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer.
Wenjie ZhuZihan ZhaoBaofu FengWenhao YuJi LiHongqian GuoRong YangPublished in: OncoTargets and therapy (2021)
CD39 may be a potential prognostic marker in BLCA, and CD8+CD39+ T cells may be selected as tumor-reactive and killing T cells for TILs therapy.